Clinical Trial Finder

Hundreds of clinical trials are rolled out around the world monthly, and many of them are designed to specifically uncover and manage the medical needs of people with sickle cell disease and trait. We keep an updated list of these global studies here, so you don’t have to go searching for them. There might be active study recruitment and enrollment happening at a site near you. Explore the list below to see the different types of studies, and use the navigation options on the left to get as specific as you would like.

Filters
Sort by
A Phase 1/2, Open-Label, Dose Escalating Study Evaluating the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of AB1 in Adult Patients With Sickle Cell Disease (SCD)

This will be an open-label, dose escalating study with a starting dose of 2mg.

Locations

118 United States sites

Age

18 Years - 45 Years

Phase

Phase 1/Phase 2

LEARN MORE
A Multi-Center, Phase 2 Gene Transfer Study Inducing Fetal Hemoglobin in Sickle Cell (GRASP, BMT CTN 2001)

A promising approach for the treatment of genetic diseases is called gene therapy.

Locations

522 United States sites

Age

13 Years - 40 Years

Phase

Phase 2

LEARN MORE
A Phase 2/3 Randomized, Multicenter Study of GBT021601 Administered Orally to Participants With Sickle Cell Disease and an Open-Label Pharmacokinetics Study in Pediatric Participants With Sickle Cell Disease

The purpose of this study is to evaluate the safety, tolerability, efficacy, pharmacokinetics and pharmacodynamics of GBT021601.

Locations

567 United States sites

114 Nigeria sites

38 Kenya sites

7 Lebanon sites

Age

6 Months - 65 Years

Phase

Phase 2/Phase 3

LEARN MORE
U01 Cooperative Assessment of Late Effects for Sickle Cell Disease Curative Therapies

Sickle Cell Disease is one of the most common genetic diseases in the United States, occurring in approximately 1 in 400 births.

Locations

340 United States sites

Age

4 Years - 65 Years

LEARN MORE
A Phase 1/2 Study to Evaluate the Safety and Efficacy of a Single Dose of Autologous Clustered Regularly Interspaced Short Palindromic Repeats Gene-edited CD34+ Human Hematopoietic Stem and Progenitor Cells (EDIT-301) in Subjects With Severe Sickle Cell Disease

The purpose of this study is to evaluate the efficacy, safety and tolerability of treatment with EDIT-301 in adult participants with severe sickle cell disease (SCD).

Locations

1057 United States sites

171 Canada site

Age

18 Years - 50 Years

Phase

Phase 1/Phase 2

LEARN MORE
A Phase IB Randomized, Placebo-Controlled Study Evaluating the Safety, Pharmacokinetics, Pharmacodynamics, and Efficacy of Crovalimab for the Management of Acute Uncomplicated Vaso-Occlusive Episodes (VOE) in Patients With Sickle Cell Disease (SCD)

The purpose of this study is to evaluate crovalimab for the treatment of a sickle cell pain crisis (also known as a VOE) that requires hospitalisation in adult and adolescent participants with SCD.

Locations

219 Spain sites

186 United States sites

180 Brazil sites

120 France sites

108 United Kingdom sites

60 Italy sites

9 Netherlands sites

9 South Africa sites

Age

12 Years - 55 Years

Phase

Phase 1

LEARN MORE
Sickle Cell Disease Treatment With Arginine Therapy (STArT) Trial

The trial of IV arginine therapy in children with Vaso-occlusive painful episodes (VOE) in sickle cell disease (SCD) is designed to further knowledge on efficacy and safety of the therapy.

Locations

620 United States sites

Age

3 Years - 21 Years

Phase

Phase 3

LEARN MORE
Home-Based Intervention for Chronic Pain in Adults With Sickle Cell Disease (HIPAS)

This project will evaluate AppliedVR's EaseVRx - a multi-modal, skills-based, 8-week, virtual reality, home intervention - in an exploratory randomized controlled trial for self-management of chronic pain among Black, young adults (ages 18-50) with sickle cell disease.

Locations

66 United States sites

Age

18 Years - 50 Years

Phase

Not Applicable

LEARN MORE
An Open Label, Observational, Prospective Registry of Participants With Sickle Cell Disease (SCD) Treated With Oxbryta® (Voxelotor)

This registry is an observational study designed to evaluate the effect of Oxbryta in individuals with SCD in a real-world setting.

Locations

1291 United States site

Age

> 4 Years

LEARN MORE
The Effect of Voxelotor on Cerebral Hemodynamic Response in Children With Sickle Cell Anemia

Voxelotor is a new drug for adolescents and adults with sickle cell disease that improves hemoglobin levels and reduces the incidence of worsening anemia.

Locations

126 United States sites

Age

4 Years - 30 Years

Phase

Phase 2

LEARN MORE